Abstract:Parasympathetic activation in the anterior eye segment regulates various physiological functions. This process, mediated by muscarinic acetylcholine receptors, also impacts intraocular pressure (IOP) through the trabecular meshwork. While FDA-approved M3 muscarinic receptor (M3R) agonists exist for IOP reduction, their systemic cholinergic adverse effects pose limitations in clinical use. Therefore, advancing our understanding of the cholinergic system in the anterior segment of the eye is crucial for developing additional IOP-reducing agents with improved safety profiles. Systems genetics analyses were utilized to explore correlations between IOP and the five major muscarinic receptor subtypes. Molecular docking and dynamics simulations were applied to human M3R homology model using a comprehensive set of human M3R ligands and 1,667 FDA-approved or investigational drugs. Lead compounds from the modeling studies were then tested for their IOP-lowering abilities in mice. Systems genetics analyses unveiled positive correlations in mRNA expressions among the five major muscarinic receptor subtypes, with a negative correlation observed only in M3R with IOP. Through modeling studies, rivastigmine and edrophonium emerged as the most optimally suited cholinergic drugs for reducing IOP via a potentially distinct mechanism from pilocarpine or physostigmine. Subsequent animal studies confirmed comparable IOP reductions among rivastigmine, edrophonium, and pilocarpine, with longer durations of action for rivastigmine and edrophonium. Mild cholinergic adverse effects were observed with pilocarpine and rivastigmine but absent with edrophonium. These findings advance ocular therapeutics, suggesting a more nuanced role of the parasympathetic system in the anterior eye segment for reducing IOP than previously thought.

Corrigendum: Deepening insights into cholinergic agents for intraocular pressure reduction: systems genetics, molecular modeling, and in vivo perspectives

Correction: Corrigendum: Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study

Deepening insights into cholinergic agents for intraocular pressure reduction: systems genetics, molecular modeling, and in vivo perspectives

Corrigendum: Evaluation of the Effectiveness of a Chronic Ocular Hypertension Mouse Model Induced by Intracameral Injection of Cross-Linking Hydrogel

Corrigendum to “Lipopolysaccharide-Induced Podocyte Injury is Regulated by Calcineurin/nfat and TLR4/MyD88/NF-κB Signaling Pathways Through Angiopoietin-like Protein 4” [genes & Diseases 9(2022) 443–455]

Correction: A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy

Corrigendum to “Angiogenesis in Pituitary Adenomas: Human Studies and New Mutant Mouse Models”

Corrigendum: Advances in retinal imaging biomarkers for the diagnosis of cerebrovascular disease

Corrigendum to “Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Coptis chinensis Franchin Polycystic Ovary Syndrome”

Corrigendum to “the Threshold of the Severity of Diabetic Retinopathy below Which Intensive Glycemic Control is Beneficial in Diabetic Patients: Estimation Using Data from Large Randomized Clinical Trials” by Yuqi Liu,Juan Li, Jinfang Ma, Nanwei Tong

Corrigendum: Involvement of Endoplasmic Reticulum Stress in Trigeminal Ganglion Corneal Neuron Injury in Dry Eye Disease

Corrigendum: Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries

Corrigendum: The GABAA Receptor Influences Pressure Overload-Induced Heart Failure by Modulating Macrophages in Mice

Corrigendum Effects of Probucol on Cultured Human Umbilical Vein Endothelial Cells Injured by Hypoxia/reoxygenation - Genet. Mol. Res. 15 (1): Gmr.15016752

Erratum: Single cell analysis of short-term dry eye induced changes in cornea immune cell populations

Corrigendum: Therapeutic potential of topical administration of acriflavine against hypoxia-inducible factors for corneal fibrosis

Corrigendum: Mechanisms of mitophagy and oxidative stress in cerebral ischemia–reperfusion, vascular dementia, and Alzheimer's disease

Correction: Corrigendum: Opportunities and challenges in modeling human brain disorders in transgenic primates

Corrigendum: The impact of patient-reported visual disturbance on dynamic visual acuity in myopic patients after corneal refractive surgery

Corrigendum: Unravelling the therapeutic potential of botanicals against chronic obstructive pulmonary disease (COPD): molecular insights and future perspectives

Erratum: Publisher's Note: "Skin-on-a-chip models: General overview and future perspectives" [APL Bioengineering 5, 030901 (2021)]